FAM122B

Across TCGA pan-cancer cohorts, FAM122B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM122B data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM122B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM122B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where FAM122B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.861	0.131	.001	51	view →
LUAD	OS	Quartile	All	0.360	0.854	.003	6	view →
HNSC	OS	Tertile	III,IV	0.780	0.956	.020	3	view →
GBM	OS	Tertile	All	0.733	0.421	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM122B–CCRCC (DFS)

Open the CCRCC breakdown →